fig3

Figure 3. Both KRAS and PTPN11 mutations confer Venetoclax resistance. KRAS mutation causes upregulation of MCL-1 and BCL2A1, while PTPN11 mutation causes upregulation of MCL-1 and BCL-xL. KRAS mutation also downregulates BCL-2 and BAX^[37].